ArticleNature communications2023
A transcriptional activator effector of Ustilago maydis regulates hyperplasia in maize during pathogen-induced tumor formation.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Plant-associated fungi co-opt ancient antimicrobials for host manipulation.Science advances · 2026Article
- Pathogenic fungus Ustilago maydis exploits the lateral root regulators to induce pluripotency in maize shoots.The New phytologist · 2026Article
- Ustilago maydis disrupts carbohydrate signaling networks to induce hypertrophy in host cells.Nature communications · 2026Article
- Take control of expression: effector-mediated modulation of the host transcriptional machinery.Frontiers in plant science · 2026Review
- TurboID-Based Proximity Labeling for Exploiting Effector Interacting Proteins in the Fungal Maize Pathogen Ustilago maydis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- The Use of Yeast Two-Hybrid Analysis to Study Protein-Protein Interactions for Ustilago maydis.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Jasmonic acid signalling is targeted by a smut fungal Tin2-fold effector.Journal of experimental botany · 2025Article
- Insight into the composition and differentiation of endophytic microbial communities in kernels via 368 maize transcriptomes.Journal of advanced research · 2025Article
- Adaptation ofFrontiers in plant science · 2024Article
- Manipulation of Auxin Signaling by Smut Fungi during Plant Colonization.Journal of fungi (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ustilago maydis causes common smut in maize, which is characterized by tumor formation in aerial parts of maize. Tumors result from the de novo cell division of highly developed bundle sheath and subsequent cell enlargement. However, the molecular mechanisms underlying tumorigenesis are still largely unknown. Here, we characterize the U. maydis effector Sts2 (Small tumor on seedlings 2), which promotes the division of hyperplasia tumor cells. Upon infection, Sts2 is translocated into the maize cell nucleus, where it acts as a transcriptional activator, and the transactivation activity is crucial for its virulence function. Sts2 interacts with ZmNECAP1, a yet undescribed plant transcriptional activator, and it activates the expression of several leaf developmental regulators to potentiate tumor formation. On the contrary, fusion of a suppressive SRDX-motif to Sts2 causes dominant negative inhibition of tumor formation, underpinning the central role of Sts2 for tumorigenesis. Our results not only disclose the virulence mechanism of a tumorigenic effector, but also reveal the essential role of leaf developmental regulators in pathogen-induced tumor formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.